JBS (JBS): Analyst Targets Point to +37% Upside Potential

Key Takeaways

• The central target of $18 is the arithmetic mean of the most recent named analyst price targets reviewed (five targets averaging $18.00), not a guaranteed outcome.
• With shares near $13, reaching $18 implies a roughly 37% upside — a substantial move from current levels.
• The named targets cluster in a tight $17–$20 range; broader aggregator data spanning 14–15 covering analysts extend from roughly $14 to $21.
• Supporting factors include a diversified global protein platform, improving cash generation, and a modest valuation versus U.S. peers.
• Principal risks are elevated leverage, margin compression, and below-break-even U.S. beef operations.
• Explore Major News, Today's Price Move, a Forecast, and Earnings coverage for deeper context on JBS.
• Discover Trending AI Robots to see AI-driven tools tracking opportunities like this.

Breaking Down the Analyst Consensus

JBS N.V., the world's largest animal-protein processor, is covered by roughly 14–15 sell-side analysts with a prevailing "Buy" rating. The most recent individual targets that can be attributed to specific firms and dates include Goldman Sachs at $17 (October 22, 2026), J.P. Morgan at $18 (October 22, 2026), Barclays at $20 (October 14, 2026), UBS at $18 (August 24, 2026), and Stephens at $17 (August 17, 2026).

Those five targets average exactly $18.00, which rounds cleanly to the $18 central target used here. The named range is narrow — $17 to $20 — while broader aggregator data indicate a wider street range of roughly $14 to $21. Notably, several firms trimmed targets through 2026 (Goldman Sachs moved from $18 to $17, and Stephens from $18 to $17), reflecting a cautious recalibration of protein-cycle assumptions, while Barclays has held the highest view at $20. The reasoning behind the mostly bullish stance centers on an expected earnings recovery, global diversification, and a valuation discount to U.S. protein peers. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Where JBS Stands in the Market Today

Shares of JBS closed near $13.13 in early November 2026, leaving the stock in the lower half of its 52-week range of $10.61 to $18.65. Reaching $18 would require a rise of roughly 37%, which is best described as a substantial move. The company's trailing-twelve-month revenue is about $91 billion, with net income near $1.1 billion and EPS (earnings per share) of roughly $1.07, implying a P/E (price-to-earnings ratio) in the low double digits.

JBS recently reported a quarterly EPS shortfall relative to consensus, and net income has declined sharply year over year, so the path toward $18 would depend on a genuine margin recovery rather than multiple expansion alone. Because $18 sits just below the prior 52-week high of $18.65, reaching it would essentially retrace the stock to the upper end of its one-year range.

Factors That Could Drive Shares Higher

• Diversified portfolio: JBS spans beef, pork, poultry, and prepared foods across North America, South America, Europe, and Oceania, spreading demand and margin exposure across protein cycles.
• Improving cash generation: Management has pointed to positive free cash flow, extended debt maturities, and plans to distribute dividends, strengthening the balance-sheet narrative.
• Valuation discount: JBS trades at a lower EV/EBITDA (enterprise value to earnings before interest, taxes, depreciation, and amortization) multiple than U.S. rivals such as Tyson Foods, a gap bulls argue should narrow.
• Strategic growth: An Asia-Pacific joint venture adds external capital for expansion while JBS retains operating control of its Australia and New Zealand businesses.

Risks That Might Hold the Stock Back

• Leverage: Net leverage remains above management's target, with roughly $24 billion in debt and about $1.3 billion in annual interest expense limiting capital-allocation flexibility.
• U.S. beef losses: The U.S. beef segment has operated below break-even, with recovery dependent on cattle supplies, herd dynamics, and trade conditions.
• Margin and demand pressure: Poultry oversupply has weighed on commodity pricing, while revenue contraction and thinner net margins have reduced operating leverage.
• Downward revisions: Several analysts lowered targets during 2026, signaling that the earnings trajectory remains uncertain.

Technical Picture and Key Levels

The 52-week range of $10.61 to $18.65 frames the technical picture. The $10.61 area marks the cycle low and a key support level, with recent trading near $13 sitting above that floor. The $14–$15 zone represents an initial hurdle, while $18.65 — the prior high — is the clearest resistance level and closely brackets the $18 target. A sustained move through the low-to-mid teens would be needed before the upper end of the range comes back into view. From what I see in the charts, these levels remain important reference points.

What to Watch Going Forward

Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms may differ. Key items to watch include quarterly earnings reports, updates on U.S. beef margins and poultry supply, progress on debt reduction, any analyst rating or target revisions, and broader protein-price and consumer-demand trends. The planned leadership transition to a new global CEO in January 2027 is also worth tracking for strategic direction. I’m watching this closely as the next earnings release approaches.

AI Daily Buy/Sell Signals for Additional Perspective

For traders seeking a systematic view, I often turn to Tickeron's AI Daily Buy/Sell Signals. These tools use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. The platform helps users discover opportunities, monitor existing positions, and spot shifting trends more efficiently. Traders looking for an additional layer of data-driven insight into JBS may find these signals a useful complement to fundamental research.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume